Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$12.15
+6.1%
$11.16
$7.58
$19.77
$433.57M0.37283,802 shs224,653 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.20
$17.03M1.19170,772 shs4.12 million shs
Genetron Holdings Limited stock logo
GTH
Genetron
$4.03
$3.98
$2.08
$4.05
$127.27M0.5151,662 shs412,603 shs
MDxHealth SA stock logo
MDXH
MDxHealth
$2.20
+4.8%
$1.93
$1.35
$3.50
$99.31M1.389,287 shs106,526 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+6.11%+3.14%+16.38%+16.38%-27.07%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-27.13%-70.18%
Genetron Holdings Limited stock logo
GTH
Genetron
0.00%0.00%0.00%-0.12%-0.12%
MDxHealth SA stock logo
MDXH
MDxHealth
+4.76%+11.68%+7.84%+45.69%-14.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity, Inc. stock logo
CELC
Celcuity
1.1743 of 5 stars
3.60.00.00.00.02.50.0
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
2.6527 of 5 stars
3.55.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
3.17
Buy$30.80153.50% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
0.00
N/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
3.00
Buy$6.50195.45% Upside

Current Analyst Ratings Breakdown

Latest ENZ, MDXH, CELC, and GTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/11/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Genetron Holdings Limited stock logo
GTH
Genetron
$94.34M1.35N/AN/A$2.63 per share1.53
MDxHealth SA stock logo
MDXH
MDxHealth
$94.51M1.10N/AN/A$0.31 per share7.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Genetron Holdings Limited stock logo
GTH
Genetron
-$117.21MN/A0.00N/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
-$38.07M-$1.15N/AN/AN/A-41.02%-492.11%-23.00%8/14/2025 (Estimated)

Latest ENZ, MDXH, CELC, and GTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/14/2025Q1 2025
MDxHealth SA stock logo
MDXH
MDxHealth
-$0.13-$0.19-$0.06-$0.19$22.62 million$24.29 million
3/31/2025Q4 2024
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.72-$0.85-$0.13-$0.85N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
13.81
2.00
1.92

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Genetron Holdings Limited stock logo
GTH
Genetron
10.74%
MDxHealth SA stock logo
MDXH
MDxHealth
N/A

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
15.78%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Genetron Holdings Limited stock logo
GTH
Genetron
N/A
MDxHealth SA stock logo
MDXH
MDxHealth
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.89 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Genetron Holdings Limited stock logo
GTH
Genetron
99331.62 millionN/ANot Optionable
MDxHealth SA stock logo
MDXH
MDxHealth
30047.29 million46.48 millionNot Optionable

Recent News About These Companies

MDxHealth SA stock logo
MDxHealth SA (NASDAQ:MDXH) Short Interest Update
MDxHealth Q1 Revenues Leap 22 Percent
MDxHealth Reports Q1-2025 Results
Lake Street Reaffirms Their Buy Rating on MDxHealth (MDXH)
MDxHealth management to meet with Lake Street
Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth sees FY25 revenue $108M-$110M, consensus $98.93M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$12.15 +0.70 (+6.11%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$12.10 -0.05 (-0.41%)
As of 06/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Genetron stock logo

Genetron NASDAQ:GTH

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

MDxHealth stock logo

MDxHealth NASDAQ:MDXH

$2.20 +0.10 (+4.76%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$2.19 -0.01 (-0.45%)
As of 06/24/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.